PLAINSBORO, N.J., Aug. 17, 2017 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present at the Wells Fargo Healthcare Conference and the Morgan Stanley Healthcare Conference in September.
- On Thursday, September 7, 2017 at 10:00 a.m. ET, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Wells Fargo Healthcare Conference in Boston, MA. A live audio webcast of the presentation can be accessed at Integra’s Investor Relations website at http://investor.integralife.com/.
- On Tuesday, September 12, 2017 at 2:05 p.m. ET, Peter Arduini, president and chief executive officer, will present at the Morgan Stanley Healthcare Conference in New York City. A live audio webcast of the presentation can be accessed at Integra’s Investor Relations website at http://investor.integralife.com/.
About Integra
Integra LifeSciences (NASDAQ:IART) is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts: Integra LifeSciences Holdings Corporation Investor Relations: Michael Beaulieu Director, Investor Relations (609) 750-2827 [email protected]


Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 



